GlucoTrack, Inc.
GCTK$0.53
+$0.24 (85.44%)
OpenLoading chart...
IndexN/A
Market Cap0.00B
Enterprise Value-0.00B
Income$-0.01B
Sales$0.00B
EmployeesN/A
P/E-0.03
P/SN/A
P/B1.23
P/C-0.23
EV/EBITDA0.20
EV/SalesN/A
EPS (ttm)-20.89
EarningsN/A
Gross Margin0.00%
Oper. Margin0.00%
Profit Margin0.00%
Volume220.79M
Shs Outstand0.00B
Change85.44%
Dividend Est.N/A
Dividend Ex-DateN/A
Perf YTDN/A
Perf YearN/A
Perf 3YN/A
Perf 5YN/A
Perf 10YN/A
IPON/A
Jul 1701:20PME.F. Hutton & Co. Serves as Exclusive Financial Advisor on Strategic Business Combination Between Glucotrack and Lōkahi Therapeutics and Exclusive Placement Agent for Approximately $5.7 Million Convertible Note Financing(globenewswire.com)08:05AMGlucotrack, Inc. and Lōkahi Therapeutics™ Announce Strategic Financing Support from E.F. Hutton & Co. in Connection with Their Recently Completed Business Combination and Future Capital Markets Initiatives(globenewswire.com)
Mar 3004:50PMGlucotrack Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights(globenewswire.com)03:17AMShort Interest in GlucoTrack, Inc. (NASDAQ:GCTK) Increases By 53.5%(defenseworld.net)
Insider Trading
View AllInsider
Type
Shares
Price
Value
Date
Balo Andrew K
Award
1.3K
—
—
Oct 3, 25
Malave Luis
Award
463
—
—
Oct 3, 25
Carter Erin Catherine
Award
386
—
—
Oct 3, 25
Balo Andrew K
Award
3.3K
—
—
Jul 11, 25
Malave Luis
Award
1.2K
—
—
Jul 11, 25
Based in Or Yehuda, Israel, GlucoTrack, Inc. is a medical technology company focused on innovating, developing, and bringing to market non-invasive glucose monitoring systems. Their primary offering, the GlucoTrack device, enables individuals with diabetes or pre-diabetes to painlessly check their blood glucose levels. This technology is available to customers both in Israel and across the globe. The company, founded in 2001, operated under the name Integrity Applications, Inc. until it officially rebranded to GlucoTrack, Inc. in November 2021.
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | $208.00K | $43.49K | $589.46K |
| Cost of Revenue | $36.00K | $13.00K | $23.00K | N/A | $47.00K | N/A | $95.56K | $140.21K |
| Gross Profit | $-36.00K | $-13.00K | $-23.00K | N/A | $-47.00K | $208.00K | $-52.08K | $449.25K |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | -119.75% | 76.21% |
| Operating Expenses | $14.51M | $7.09M | $4.41M | $4.04M | $3.08M | $-3.30M | $-6.59M | $-10.13M |
| Operating Income | $-14.55M | $-7.10M | $-4.43M | $-4.04M | $-3.13M | $3.51M | $6.54M | $10.58M |
| Operating Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 1685.58% | 15035.41% | 1794.15% |
| Net Income | $-22.60M | $-7.10M | $-4.43M | $-4.07M | $-2.70M | $-3.52M | $-6.72M | $-10.33M |
| Net Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1690.38% | -15442.01% | -1752.24% |
| EPS (Basic) | $60.76 | $-38.30 | $-28.66 | $-26.32 | $-17.88 | $-29.50 | $0.00 | $0.00 |
| EBITDA | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Discover more
You may be interested in